(Total Views: 517)
Posted On: 02/25/2024 9:16:11 PM
Post# of 154137
Mitch Cohen interviewed on previous post.
___________________________________________________________________________
BIOPROCESS ONLINE
"The results of this clinical trial establish the First Ever proof of concept for a long-acting HIV Therapy with the potential for self-administration," said Melanie A.Thompson M.D., Principal Investigator of the AIDS Research Consortium of Atlanta and the lead author of the CROI presentation.
"Given its favourable Tolerability profile and potential for convenient weekly dosing by patients, subcutaneous PRO140 holds promise in providing a POTENT and NOVEL treatment option for individuals living with HIV."...February 13, 2009. Has it really been 15 years???
___________________________________________________________________________
BIOPROCESS ONLINE
"The results of this clinical trial establish the First Ever proof of concept for a long-acting HIV Therapy with the potential for self-administration," said Melanie A.Thompson M.D., Principal Investigator of the AIDS Research Consortium of Atlanta and the lead author of the CROI presentation.
"Given its favourable Tolerability profile and potential for convenient weekly dosing by patients, subcutaneous PRO140 holds promise in providing a POTENT and NOVEL treatment option for individuals living with HIV."...February 13, 2009. Has it really been 15 years???
(2)
(0)
